TXNIP-IN-1 是一种硫氧还蛋白-硫氧还蛋白相互作用蛋白 (TXNIP-TRX) 复合物抑制剂，详细信息请参考专利文献US20200085800A1 中的化合物 1。TXNIP-IN-1 可用于 TXNIP-TRX 复合物相关代谢紊乱 (糖尿病)、心血管疾病或炎症疾病的研究。

TXNIP-IN-1 is TXNIP-TRX (thioredoxin-interacting protein- thioredoxin) complex inhibitor extracted from patent US20200085800A1, Compound 1. TXNIP-IN-1 can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease.

Solid

TXNIP-TRX complex

TXNIP-IN-1 bocks high glucose (HG induced) TXNIP-TRX complex formation.
TXNIP-IN-1 (1.25-5 μM) reduces HG-induced expression of TNF in monocytes.
TXNIP-IN-1 (1.25-5 μM; 72 hours) inhibits TXNIP mRNA expression in THP1 cells.
TXNIP-IN-1 (0.3-10 μM; 72 hours) inhibits TXNIP mRNA expression in murine RAW macrophages.
TXNIP-IN-1 (5-20 μM; 72 hours) decreases TXNIP but not TNF-alpha mRNA levels in MIN6 cells.
TXNIP-IN-1 (0.62-5 μM; 72 hours) affects TXNIP and TNF-alpha mRNA expression in human pancreas 1.1B4 beta cells.
TXNIP-IN-1 (5 μM; 16-72 hours) inhibits c-TRX interaction in THP1 cells cultured in 25mM glucose.
TXNIP-IN-1 targets TXNIP mRNA in human pancreatic islets.
has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Rama Natarajan, et al. Txnip-trx complex inhibitors and methods of using the same. US20200085800A1.

In Vitro: DMSO : 50 mg/mL (201.43 mM; Need ultrasonic)配制储备液